Tom Mendell

Provista Diagnostics, your neighborhood early detection center based in Alpharetta, GA, is simplifying health diagnostics. Provista is creating empowering diagnostics for Women's Health helping patients and clinicians make better clinical decisions for the enhancement of health and quality of life. Provista is investing 100% of our COVID-19 PCR testing profits in creating life-saving diagnostic solutions for a healthier today and tomorrow with Videssa Breast Cancer Detection being launched first as early as 4thQ 2022.​

Topgolf is the ultimate instigator of play. Thanks to our 100+ venues around the globe, which are powered by industry-leading Toptracer technology, were leading the charge of modern golf. We offer a variety of tech-driven games, a top-tier food and drink menu, space to host large events, and a vibe focused on more play for all. To learn more, plan an event, or make plans to come play around, visit topgolf.com.

Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, we’re dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertix’s Guardian™ is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.

Provista Diagnostics, your neighborhood early detection center based in Alpharetta, GA, is simplifying health diagnostics. Provista is creating empowering diagnostics for Women's Health helping patients and clinicians make better clinical decisions for the enhancement of health and quality of life. Provista is investing 100% of our COVID-19 PCR testing profits in creating life-saving diagnostic solutions for a healthier today and tomorrow with Videssa Breast Cancer Detection being launched first as early as 4thQ 2022.​